GLAUKOS CORP (GKOS)
NYSE • Healthcare
Last close at July 27, 2026 at 20:00 UTC
Fundamentals Charts
About GLAUKOS CORP
Glaukos Corporation trades on the NYSE under GKOS and develops ophthalmic medical devices, centered on minimally invasive glaucoma products. Its FY2025 revenue was $507.4 million. The company sells iStent, iStent inject, and iStent inject W for use in cataract surgery and in treating mild-to-moderate open-angle glaucoma.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
GLAUKOS CORP's Technical Indicators Summary
GKOS at 153.58 presents a broadly bullish alignment across moving averages while trend conviction remains modest. Momentum indicators like RSI and short-term momentum are positive, and the stock trades above its 20-, 50-, 100- and 200-day averages, which supports the Buy view; the 10-day average is only marginally different. ADX is low, indicating limited trend strength, and ATR near 3.6% points to moderate volatility. On the downside, OBV shows limited volume confirmation even as the pivot level sits below the current price. Technical takeaway: Buy—moving averages back the uptrend but weak trend strength and volume temper conviction.
| Indicator | Value |
|---|---|
RSI (14) | 62.30 |
Stochastic %K (14, 3, 3) | 57.20 |
CCI (20) | 47.46 |
WPR (14) | -43.16 |
Momentum (10) | 0.86 |
MFI | 62.90 |
MACD Level (12, 26) | 5.40 |
Bollinger Bands | $139.55 - $161.83 |
ATR (14) | $5.57 (3.63%) |
ADX (14) | 16.59 |
OBV | 3,155,160 |
Classic Pivot Point | $151.84 |
Fibonacci Pivot Point | $151.84 |
Simple Moving Averages | $115.34 - $154.14(5 indicators) |
Exponential Moving Averages | $117.14 - $152.96(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
Closing levels leave GKOS heading into an earnings window 2 days out on 29 July. End-of-day, the peer group was modestly in the green at 0.53%, providing a small boost to sentiment. GKOS completes patient enrollment for its Groundbreaking G study, a potential catalyst for glaucoma pipeline.
Trading Volume
Above 10d avg 519.2K
704.8K
vs S&P 500 Today
Underperforming Market
-1.08%
52-Week Position
Upper range
89.1%
Updated: July 27, 2026 at 20:44 UTC